Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
glioblastoma multiforme (GBM)
Biotech
MimiVax's glioblastoma vaccine misses primary endpoint in ph. 2
Long-term survival analysis shows approximately 42% of SurVaxM-treated patients 65 and under were alive through 30 months with no deaths at 54 months.
Marissa Russo
Oct 7, 2026 8:00am
‘Low tech’ chemotherapy nanoparticles treated deadly brain tumor
Jul 29, 2026 2:30pm
Potential brain tumor pill shrinks tumors in mice
Jan 28, 2026 2:00pm
'Quantum therapeutic' sparks glioblastoma cells to self-destruct
Sep 18, 2023 11:00am
Souped-up oncolytic virus warms up cold brain cancer tumors
Nov 11, 2022 12:56pm
Kazia dropped from global umbrella trial to treat brain cancer
Aug 1, 2022 1:45pm
